In 2022, the National Cancer Institute recognized three of our radiation oncologists for their participation in clinical trials. Matthew Cheney, MD, PhD, received the Gold Award for Treatment and Cancer Control, Screening, and Prevention Trial Accrual, contributing 10-39 accruals. Whitney Beeler, MD, and Cornelius McGinn, MD, received the Silver Award for Treatment and Cancer Control, Screening, and Prevention Trial Accrual, contributing 5-9 accruals. The radiation oncology division at Spectrum is currently enrolling patients in 19 different clinical trials.
Clinical trials are essential for the advancement of oncology medicine as these studies test new methods of screening, prevention, diagnosis, or treatment of a disease and help identify the best treatment options for future cancer care.
Clinical trials are important for patients on several levels. First and foremost, clinical trials provide the foundation for the development of evidence-based guidelines. They inform the development of treatment plans and pave the way for continual improvements in cancer care and patient outcomes. Additionally, clinical trials often provide patients an additional treatment option when other proven methods have not been successful.
Our team of board-certified and fellowship-trained radiation oncologists deliver over 30,000 treatments to adults and children every year. Learn more about our radiation oncology services.